-+ 0.00%
-+ 0.00%
-+ 0.00%

Palisade Bio's Data From Its Lead Program, PALI-2108, Selected For Poster Presentation At Digestive Disease Week 2026

Benzinga·04/16/2026 12:54:09
Listen to the news

Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT

Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that data from its lead program, PALI-2108, has been selected for poster presentation at Digestive Disease Week® (DDW) 2026, taking place May 2–5, 2026 in Chicago.

The Company will be in attendance alongside members of its Clinical Advisory Board (CAB), further reinforcing its engagement with leading experts in inflammatory bowel disease as it advances PALI-2108 toward the clinic.